OpenAI has introduced a life sciences ai model called GPT-Rosalind, which aims to accelerate drug development. Other companies, such as Anthropic, are also working on ai initiatives for drug discovery, including internal programs and partnerships with other firms. The introduction of these ai models and related technologies may potentially speed up research and development in the pharmaceutical industry.